SCHEMBL572782

SCHEMBL572782

CC(N1CCNCC1)S(=O)(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
LMNA P02545 1/20 0.37
CYP3A4 P08684 1/20 0.37
GABRA1 P14867 1/20 0.37
TSHR P16473 1/20 0.37
GABRG2 P18507 1/20 0.37
NFKB1 P19838 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRA6 Q16445 1/20 0.37
CHRM5 P08912 1/20 0.35
CHRM3 P20309 1/20 0.35
KDM4E B2RXH2 1/20 0.34
SIGMAR1 Q99720 1/20 0.33
OPRD1 P41143 5/20 0.33
SLC6A2 P23975 1/20 0.32
KMT2A Q03164 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piperazine SCHEMBL4732179 0.91 LMNA (0.37) CHRM2CHRM1LMNACYP3A4GABRA1
SCHEMBL62393 0.84 KDM4E (0.32) LMNAKDM4E
SCHEMBL28080241 0.80 CHRM2 (0.40) CHRM2CHRM1CHRM5CHRM3KDM4E
SCHEMBL28122578 0.79 FDPS (0.34) KDM4ESLC6A2ALDH1A1SMN1; SMN2
Water SCHEMBL28800260 0.79 KDM4E (0.30) KDM4E
Sulfuric Acid SCHEMBL27952192 0.78 CHRM2 (0.39) CHRM2CHRM1LMNACYP3A4GABRA1
SCHEMBL28214258 0.78 CHRM2 (0.36) CHRM2CHRM1LMNACYP3A4GABRA1
SCHEMBL9172138 0.77 LMNA (0.39) CHRM2CHRM1LMNACYP3A4GABRA1
SCHEMBL987341 0.77 SIGMAR1 (0.30) SIGMAR1
SCHEMBL5047965 0.77 FDPS (0.38) TSHRKDM4ESLC6A2KMT2ACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260077092-A1 INJECTABLE COLLAGEN IMPLANTS AND COMPOSITIONS AND RELATED SYSTEMS, AND METHODS OF PREPARATION AND USE THEREOF Miach Orthopaedics, Inc. (US) 2026-03-19 US claimed
WO-2024118032-A1 SPERM WASHING AND SPERM FREEZING SOLUTIONS ENRICHED WITH QUERCETIN ISTANBUL MEDIPOL UNIVERSITESI TEKNOLOJI TRANSFER OFISI ANONIM SIRKETI (TR) 2024-06-06 WO claimed
WO-2024057324-A1 PLASMA-ACTIVATED COMPOSITIONS AND METHODS OF USE THEREOF NOVA PLASMA LTD. (IL) 2024-03-21 WO claimed
WO-2024047639-A1 INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2024-03-07 WO claimed
WO-2023235132-A1 CELL DELIVERY VEHICLE AND METHODS OF USING THE SAME BLUEROCK THERAPEUTICS LP (US) 2023-12-07 WO claimed
WO-2023225331-A1 EXTENDED LIVE CELL BARCODING APPROACH FOR MULTIPLEXED MASS CYTOMETRY BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-11-23 WO claimed
WO-2023212160-A1 DRUG RELEASING HYDROGELS, MATERIALS, DEVICES, AND USES RELATED THERETO EMORY UNIVERSITY (US) 2023-11-02 WO claimed
EP-4240322-A1 RESPIRABLE AQUEOUS PHARMACEUTICAL COMPOSITION COMPRISING A POLYPEPTIDE FOR CORONA VIRUS TREATMENT AND NEUTRALIZATION Masker Med Tech AB (SE) 2023-09-13 EP claimed
EP-4189393-A1 RELIABLE AND SCALABLE METHODS OF DETECTION AND PLATFORM FOR CONSUMER MEDICAL DEVICES Simple Healthkit, Inc. (US) 2023-06-07 EP claimed
WO-2023079301-A1 ASSAYS USING MUTANT COMPLEMENT FACTOR I VARIANTS WITH DECREASED ACTIVITY FREELINE THERAPEUTICS LIMITED (GB) 2023-05-11 WO claimed
WO-2017132604-A1 METHODS AND APPARATUS FOR DETECTING COMPOUNDS IN LIQUIDS Undercover Colors, Inc. (US) 2017-08-03 WO claimed
CN-106278524-A The preparation method and applications of bio-feritlizer 苏州益可泰电子材料有限公司 2017-01-04 CN claimed
WO-2015013177-A2 RAPID DETECTION OF CARBAPENEMASE AND BETA-LACTAMASE PRODUCING BACTERIA SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2015-01-29 WO claimed
EP-2764099-A1 ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF Mitra Biotech Private Limited (IN) 2014-08-13 EP claimed
WO-2013050962-A1 ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF MITRA BIOTECH PRIVATE LIMITED (IN) 2013-04-11 WO claimed
WO-2010068759-A1 PHARMACEUTICAL FORMULATIONS OF BIODEGRADABLE BIOCOMPATIBLE CAMPTOTHECIN-POLYMER CONJUGATES MERSANA THERAPEUTICS, INC. (US) 2010-06-17 WO claimed
EP-1067907-A1 OCULAR IRRIGATING SOLUTION UNIVERSITY OF BRISTOL (GB) 2001-01-17 EP claimed
WO-1999051204-A1 OCULAR IRRIGATING SOLUTION UNIVERSITY OF BRISTOL (GB) 1999-10-14 WO claimed
EP-0396584-A1 ASSAY OF SALICYLATES OR REDUCED PYRIDINE NUCLEOTIDES. HEALTH LAB SERVICE BOARD (GB) 1990-11-14 EP claimed
WO-1989005356-A1 ASSAY OF SALICYLATES OR REDUCED PYRIDINE NUCLEOTIDES THE PUBLIC HEALTH LABORATORY SERVICE BOARD (GB) 1989-06-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260077092-A1 INJECTABLE COLLAGEN IMPLANTS AND COMPOSITIONS AND RELATED SYSTEMS, AND METHODS OF PREPARATION AND USE THEREOF COL2A1, COL1A1, MMP1 CHRM2 4062/4885CHRM1 4306/4885LMNA 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.